SMAD3 activation in pancreatic stellate cells correlates with PTGDR2 expression and favorable stromal features in pancreatic cancer
Pancreatology · 2026-05 · 26 (3) · 459-468
DOI: 10.1016/j.pan.2026.03.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pancreatology, 2026-05. Verfasst von Naohiro Hirano und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. Hauptthemen laut MEDLINE: Smad3 Protein, Pancreatic Stellate Cells, Pancreatic Neoplasms, Receptors, Prostaglandin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
BACKGROUND: Pancreatic cancer is characterized by a dense tumor microenvironment enriched with cancer-associated fibroblasts (CAFs), which display context-dependent tumor-promoting and tumor-restraining properties. However, the molecular basis of stromal heterogeneity remains incompletely understood. METHODS: We examined stromal responses of pancreatic stellate cells (PSCs), a major source of CAFs, using an orthotopic mouse co-implantation model, RNA sequencing, conditioned medium-based functional assays, and immunohistochemical analysis of resected pancreatic cancer specimens. RESULTS: Co-implantation of PSCs with pancreatic cancer cells was associated with smaller primary tumor volumes and selective activation of SMAD3 in PSCs. Cancer cell-derived conditioned medium activated SMAD3 signaling in PSCs but not in cancer cells, suggesting cell type-specific pathway activation. Transcriptomic analysis identified prostaglandin D2 receptor 2 (PTGDR2) as a gene upregulated in association with SMAD3 activation, and its expression decreased following SMAD3 inhibition. Functional assays showed that SMAD3 activation was associated with modulation of PTGDR2 and inflammatory gene expression in PSCs. In clinical samples, higher p-SMAD3 expression in CAFs correlated with favorable overall survival. CONCLUSIONS: SMAD3 activation in PSCs was observed in association with PTGDR2 expression, altered inflammatory profiles, and reduced tumor growth in vivo. These findings support the presence of distinct stromal phenotypes in pancreatic cancer and warrant further investigation into CAF modulation strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
- Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. Electronic address: koetsu.inoue.d5@tohoku.ac.jp.
- Department of Investigative Pathology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
- Department of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Hirano, N., Inoue, K., Aoki, S., Yoshimachi, S., Sato, H., Shimura, M., Taniguchi, H., Iseki, M., Douchi, D., Murakami, K., Maeda, S., Miura, T., Ishida, M., Mizuma, M., Masamune, A., & Unno, M. (2026). SMAD3 activation in pancreatic stellate cells correlates with PTGDR2 expression and favorable stromal features in pancreatic cancer. Pancreatology, 26(3), 459-468. https://doi.org/10.1016/j.pan.2026.03.007
Vancouver
Hirano N, Inoue K, Aoki S, Yoshimachi S, Sato H, Shimura M, et al. SMAD3 activation in pancreatic stellate cells correlates with PTGDR2 expression and favorable stromal features in pancreatic cancer. Pancreatology. 2026;26(3):459-468. doi:10.1016/j.pan.2026.03.007
BibTeX
@article{Hirano2026,
author = {Hirano, Naohiro and Inoue, Koetsu and Aoki, Shuichi and Yoshimachi, Shingo and Sato, Hideaki and Shimura, Mitsuhiro and Taniguchi, Hajime and Iseki, Masahiro and Douchi, Daisuke and Murakami, Keigo and Maeda, Shimpei and Miura, Takayuki and Ishida, Masaharu and Mizuma, Masamichi and Masamune, Atsushi and Unno, Michiaki},
title = {SMAD3 activation in pancreatic stellate cells correlates with PTGDR2 expression and favorable stromal features in pancreatic cancer},
journal = {Pancreatology},
year = {2026},
volume = {26},
number = {3},
pages = {459--468},
doi = {10.1016/j.pan.2026.03.007}
}
EUVIMED